Element Materials Technology (Element), a leading global Testing, Inspection and Certification (TIC) company, has launched an integrated offering for its pharmaceutical services.
This strategic initiative brings together the expertise and capabilities of its recent North American acquisitions of Nanosyn and JMI labs into its existing Life Sciences business. This integration creates a team of over 1,400 scientists and chemists operating across a worldwide network of laboratories.
Combining the Contract Development & Manufacturing Organisation (CDMO) and Contract Research Organisations (CRO) allows Element to provide robust support to its customers at every stage of their product's life cycle.
The industry contends with supply chain disruptions, escalating development costs, staffing constraints, and manufacturing delays
- Marie Keeley, VP Life Sciences America at Element
The large team combines extensive knowledge in scientific and regulatory fields with a wide selection of advanced equipment and creative solutions, ensuring it can deliver exceptional expertise and innovation.
With a strategic location in the San Francisco Bay Area, Nanosyn’s laboratories function as a CDMO, providing a seamless platform to cater to customers throughout the development life cycle.
Boasting a history dating back to 1998, Nanosyn has a remarkable track record of advancing small molecules from initial hits to Investigational New Drugs (IND), supported by an exceptional team of over 50 scientists equipped with cutting-edge technology and efficient operations.
Nanosyn’s laboratory in Santa Clara specialises in chemistry and drug discovery services, housing one of the largest chemical inventories of any pharmaceutical synthesis lab in the US. The dedicated scientists at Santa Clara also boast co-authorship of over 300 patents.
The company’s Santa Rosa lab is an FDA-inspected kilo lab facility, offering manufacturing capabilities across 6 GMP suites and 2 class 10,000 cleanrooms, alongside state-of-the-art R&D facilities.
Marie Keeley, VP Life Sciences America at Element said: “Pharmaceutical companies face a myriad of challenges in their pursuit of developing new products. The industry contends with supply chain disruptions, escalating development costs, staffing constraints, and manufacturing delays, making the process of bringing a new drug to market more demanding than ever before.”